ArticleDiscover oncology2025
Uncovering the mediating role of CSF metabolites in the gut microbiota-glioblastoma axis via causal mediation analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiota-Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma.Brain and behavior · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma is a lethal brain tumor with poor prognosis and limited early diagnostic tools. The gut microbiota and its metabolites may influence glioblastoma progression through the gut-brain axis.
methodsWe employed Mendelian randomization and Generalized Summary-data-based Mendelian Randomization to explore causal relationships among 473 gut microbial taxa, 338 cerebrospinal fluid metabolites, and glioblastoma risk in Finnish individuals. Mediation analysis was conducted to identify key pathways linking gut microbes, metabolites, and glioblastoma development.
resultsCoprobacillus cateniformis was positively associated with glioblastoma (OR = 1.7363,95%CI:1.0541–2.8600,P = 0.030). The cerebrospinal fluid metabolite S-1-pyrroline-5-carboxylate was negatively associated with glioblastoma (OR = 0.7270,95%CI:0.5506–0.9598,P = 0.024). Additionally, Coprobacillus cateniformis was negatively associated with S-1-pyrroline-5-carboxylate (OR = 0.8933, 95%CI:0.7994–0.9982,P = 0.046). Mediation analysis indicated that S-1-pyrroline-5-carboxylate served as a mediator in the pathway through which Coprobacillus cateniformis promotes glioblastoma development, with a mediation effect ratio of 6.1%.
conclusionThis study reveals a potential causal pathway linking Coprobacillus cateniformis to glioblastoma through S-1-pyrroline-5-carboxylate. These findings highlight a novel gut–cerebrospinal fluid–brain axis and suggest potential microbial and metabolic biomarkers for glioblastoma diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.